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The circulating microRNAs (miRNAs) associated with type 2 diabetes (T2D) in elderly patients are still being deﬁned. To identify
novel miRNA biomarker candidates for monitoring responses to sitagliptin in such patients, we prospectively studied 40 T2D
patients (age> 65) with HbA1c levels of 7.5–9.0% on metformin. After collection of baseline blood samples (t0), the dipeptidyl
peptidase-IV (DPP-IV) inhibitor (DPP-IVi) sitagliptin was added to the metformin regimen, and patients were followed for 15
months. Patients with HbA1c< 7.5% or HbA1c reduction> 0.5% after 3 and 15 months of therapy were classiﬁed as
“responders” (group R, n = 34); all others were classiﬁed as “nonresponders” (group NR, n = 6). Circulating miRNA proﬁling
was performed on plasma collected in each group before and after 15 months of therapy (t0 and t15). Intra- and intergroup
comparison of miRNA proﬁles pinpointed three miRNAs that correlated with responses to sitagliptin: miR-378, which is a
candidate biomarker of resistance to this DPP-IVi, and miR-126-3p and miR-223, which are associated with positive responses
to the drug. The translational implications are as immediate as evident, with the possibility to develop noninvasive diagnostic
tools to predict drug response and development of chronic complications.
1. Introduction
With >400 million patients worldwide, type 2 diabetes (T2D)
is among the most frequently diagnosed metabolic disorders.
T2D is a multifactorial disease: genetic, lifestyle, and envi-
ronmental factors combine to render target tissues insensi-
tive to insulin, resulting in increasingly high blood levels of
glucose. The disease is associated with serious and frequently
disabling long-term complications, including cardiovascular
disease, renal failure, neuropathy, and blindness, and it is
therefore one of the leading causes of the global increase
in morbidity and mortality [1–3]. Outcomes could be
improved by earlier diagnosis, while the disease is still in
the initial phase, and more rational use of currently avail-
able therapies (i.e., targeting drugs to the patients most
likely to beneﬁt from them). For this reason, there is an
urgent need for new biomarkers with potential applica-
tions in the prevention and early diagnosis of T2D and
for predicting its response to therapy, especially for fragile
elderly patients [1, 2, 4].
Recently, microRNAs (miRNAs)—short (21-22 nucleo-
tides), single-stranded, noncodingRNAs—havebeendetected
in human plasma and other biological ﬂuids, and in some
cases, their expression proﬁles prove to be disease-speciﬁc
[5–9]. Compared with many more conventional biomarkers,
miRNAs oﬀer several advantages, such as high stability,
even under drastic conditions. In addition, miRNAs have
been identiﬁed as major regulators of pancreatic β-cell
mass and function, that is, the two key factors in the
pathogenesis of T2D [9–11]. For these reasons, they are
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considered a promising source of biomarkers for diagnosing
and staging T2D as well as for predicting their response to
therapy [1, 12].
Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone that stimulates insulin release by β-cells in a
glucose-dependent manner and, at the same time, reduces
glucagon secretion by alpha-cells. GLP-1-based therapeutic
strategies have an increasing role in T2D treatment and
consist of GLP-1 agonists and dipeptidyl peptidase-IV
(DPP-IV) inhibitors (gliptins) [13]. In detail, gliptins are
able to rapidly deactivate GLP-1, resulting in the decrease
in insulin production, and are a recent addition to the class
of oral glucose-lowering drugs used to treat T2D. Several
components of this class, including vildagliptin, sitagliptin,
saxagliptin, alogliptin, and linagliptin, have already been
approved for this indication by the US Food and Drug
Administration or by the European Medicines Agency;
others are awaiting for approval or still in development.
Gliptins can be used as single-agent therapy or combined
with other antidiabetic agents (e.g., metformin) when the
latter fail to produce or maintain adequate glycemic control
[14, 15]. DPP-IVi would indeed induce insulin secretion in
a glucose-dependent manner, with minimal risk of hypogly-
cemia; accordingly, DPP-IVi can produce a signiﬁcant
reduction in HbA1c. Moreover, they are usually well toler-
ated, with no weight gain or gastrointestinal side eﬀects
[15–18]. Interestingly, they also appear to oﬀer added ben-
eﬁts consisting of the epigenetically mediated restoration of
normal gene activity in dysfunctional pancreatic islets [19].
A recent study in diabetic CD1 mice also indicates that
gliptin therapy can ameliorate T2D-related kidney ﬁbrosis
[20], an eﬀect that was mediated by the drug’s induction
of the expression of miR-29.
These ﬁndings prompted us to investigate the circulat-
ing miRNA proﬁle of elderly patients with poorly con-
trolled T2D and to identify the changes it undergoes
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Figure 2: Glycemic control statuses of the patients at baseline and 3
and 15 months after initiation of metformin + sitagliptin. All 40
patients in poor metabolic control were enrolled. HbA1c levels
were evaluated after 3 and 15 months from the addition of
sitagliptin. On the basis of HbA1c values, patients were divided
into responders and nonresponders. All patients showed an initial
metabolic response to therapy (t3), whereas after 15 months (t15),
34/40 were responders. Based on this information, patients were
divided into ﬁve groups: (1) t0 responder samples (R-t0), (2) t0
nonresponder samples (NR-t0), (3) t3 responder samples (R-t3), (4)
t15 responder samples (R-t15), and (5) t15 nonresponder samples
(NR-t15). miRNA proﬁling was performed at baseline and after 15
months of sitagliptin addition.
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Figure 1: Experimental design for the identiﬁcation of circulating miRNAs in T2D patients. The duration of the study was 2 years. The blue
horizontal arrow indicates the duration of the diﬀerent phases of the project. The red vertical arrows indicate the main study periods.
In year 1, patients were enrolled and started on metformin + sitagliptin (see Materials and Methods for details). After 3 and 15 months of
treatment (t3 and t15), HbA1c values were reassessed and patients were classiﬁed as nonresponders (NR) or responders (R). Plasma
miRNA levels at baseline (t0) and t15 from groups R and NR were compared as indicated. Comparison of plasma pools: (1) NR-t0 versus
R-t0, (2) R-t15 versus R-t0, (3) NR-t15 versus NR-t0, and (4) NR-t15 versus R-t15.
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during DPP-IVi therapy with sitagliptin. The plasma levels
of three miRNAs (miR-1208, miR-550a-3p, and miR-30c-5p)
displayed directionally similar trends in responders and non-
responders during the 15 months of sitagliptin treatment.
These miRNAs thus appear to be modulated by sitagliptin,
but not correlated with metabolic response. In contrast,
three other miRNAs emerged as promising candidates for
use as positive (miR-126-3p and miR-223) and negative
(miR-378) biomarkers of responses to sitagliptin therapy
in this elderly patient population.
2. Materials and Methods
2.1. Patients. The Ethics Committee of the Tor Vergata
University of Rome Medical Center approved this study pro-
tocol, and written informed consent was obtained from all
patients involved in the study. Patients (males and females)
were eligible for enrollment in the study if they met all the
following criteria: (1) age> 65 years, (2) a ≥1-year history of
T2D, and (3) poor glycemic control (HbA1c levels ranging
from 7.5% to 9.0%) on current treatment with maximum-
Table 1: Characteristics of R and NR patients enrolled in the study.
Parameters Responders (R) Nonresponders (NR)
Age (y) 66.62± 2.31 67.89± 2.24
Gender, males/females (n) 17/17 4/2
Time since T2D diagnosis (y) 11± 2 10± 3
Time points (in months) t0 t3 t15 t0 t3 t15
Body weight (kg) 72.30± 4.92 70.36± 4.89 70.43± 5.23 79.10± 12.19 78.57± 13.25 79.33± 12.99
HbA1c (%) 7.75± 0.38 6.38± 0.18 7.10± 0.28 7.59± 0.16 6.73± 0.39 7.81± 0.51
Data are means ± SD unless indicated otherwise.
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Figure 3: Venn diagram of circulating miRNAs detected in the elderly T2D cohort and in the R and NR subcohorts. Patients were classiﬁed as
responders (R) or nonresponders (NR) based on their glycemic control status after 15 months of treatment with metformin + sitagliptin (t15).
Venn diagrams show the number of miRNAs detected in NR and R plasma samples collected (a) before the start of combined therapy
(baseline, t0) and (b) at t15 and (c) at both t0 and t15.
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dose metformin. The following exclusion criteria were
applied at baseline and during follow-up: insulin therapy,
major organ failure (e.g., congestive heart failure and respira-
tory and/or hepatic insuﬃciency), positive history for atrial
ﬁbrillation or a coronary or cerebrovascular event during
the previous 6 months, known neoplastic disease, and/or
acute infections.
Blood samples for HbA1c measurement and circulating
miRNA proﬁling (details below) were drawn upon enroll-
ment (t0), and the patients were then started on sitagliptin
(100mg once daily) as an adjunct to their metformin therapy.
Glycemic control was assessed 3 and 15 months later (t3 and
t15, resp.) (as shown in Figure 1). Patients were classiﬁed as
“responders” (R) if they exhibited good glycemic control at
both time points, reﬂected by an HbA1c level of <7.5% or
an HbA1c reduction of >0.5% relative to the level recorded
at t0. Patients who failed to meet these criteria were classiﬁed
as “nonresponders” (NR). On the basis of these ﬁndings,
plasma samples were pooled into the following ﬁve groups:
(1) baseline samples frompatients that emerged as responders
(R-t0 pool), (2) baseline samples from nonresponders (NR-t0
pool), (3) t3 samples from responders (R-t3 pool), (4) t15
samples from responders (R-t15 pool), and (5) t15 samples
from nonresponders (NR-t15 pool) (Figure 2). Characteristics
of the patients enrolled in the study are reported in Table 1.
2.2. Isolation and Proﬁling of Circulating miRNAs. For
miRNA studies, 5mL of blood was collected from each
patient in EDTA-treated tubes. Within 30 minutes of collec-
tion, the samples were centrifuged for 10 minutes at 2000×g
at room temperature (RT), and the plasma thus obtained was
divided into 250μL aliquots and stored at −80°C. To
eliminate the risk of bias related to hemolysis [21], all plasma
samples were visually assessed and those that were hemo-
lyzed, icteric, or lipemic were excluded from the analysis.
We also evaluated the expression of miRNAs susceptible to
hemolysis, such as miR-324-3p, miR-454, and miR-652
[21]. Indeed, these miRNAs were not detected in our sam-
ples, conﬁrming that none of the samples utilized in the study
were hemolyzed.
Plasma samples from all patients in a given group (see
above) were thawed on ice and pooled. A miRNA ABC
puriﬁcation kit (Applied Biosystems, Thermo Scientiﬁc)
was used, according to the manufacturer’s instructions.
Brieﬂy, 50μL of each plasma pool was mixed with 100μL
of lysis buﬀer and centrifuged brieﬂy before the addition of
100nM of ath-miR-159a (used as a positive external control).
Samples were then mixed with freshly prepared magnetic
beads (80× 106) and incubated in a magnetic rack (40min
at 30°C). Bead-hybridized miRNAs were then washed to
remove any contaminants. Elution buﬀer (50μL) was added,
and the sample was incubated for 3 minutes in a Thermo-
Mixer (1200 rpm, 70°C) and placed for 1 minute in a
magnetic rack to clear solutions. The supernatants were then
transferred into clean tubes and placed on ice.
miRNAs were reverse-transcribed using speciﬁc primers
according to Applied Biosystems protocols. The cDNAs
were preampliﬁed using reagents from Applied Biosystems
(Thermo Scientiﬁc), and the products were subjected to
miRNA expression proﬁling. The latter was performed by
RT-qPCR with Taqman Low-Density Array microﬂuidic
cards (Human miR v3.0, Applied Biosystems), as previously
described [22].
2.3. miRNA Expression Analysis. Statistical analysis was per-
formed with StatMiner™ software, v. 5.0 (Integromics™)
[23]. miRNA expression levels in plasma pools were subjected
Table 2: miRNAs with known links to T2D found in baseline (t0)
plasma pools from groups NR and R.
T2D-linked microRNAs at t0
hsa-let-7d
hsa-miR-103
hsa-miR-126
hsa-miR-130b
hsa-miR-142-3p
hsa-miR-144
hsa-miR-145
hsa-miR-146a
hsa-miR-155
hsa-miR-17-5p
hsa-miR-186
hsa-miR-191
hsa-miR-192
hsa-miR-195
hsa-miR-197
hsa-miR-20b
hsa-miR-21
hsa-miR-222
hsa-miR-223
hsa-miR-23a
hsa-miR-26a
hsa-miR-27a
hsa-miR-29a
hsa-miR-30d
hsa-miR-30e
hsa-miR-342
hsa-miR-34a
hsa-miR-375
hsa-miR-378
hsa-miR-423-5p
hsa-miR-451a
hsa-miR-483-3p
hsa-miR-486
hsa-miR-571
hsa-miR-572
hsa-miR-593
hsa-miR-661
hsa-miR-770-5p
hsa-miR-9
hsa-miR-92a
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to global expression normalization, and relative levels were
calculated with the comparative threshold cycle (Ct) method.
miRNAs with Ct values> 33 were excluded. Diﬀerential
expression between groups was assessed with the limma
test and considered statistically signiﬁcant when P values
were <0.05. Heat maps were generated in the R environment
(http://www.r-project.org/), using diﬀerentially expressed
miRNAs as input. The Bray-Curtis and average linkage
methods were used to cluster samples (hclust) and generate
heat maps (heatmap.2).
3. Results and Discussion
All 40 enrolled patients completed 15 months of treatment
with metformin+ sitagliptin without occurrence of adverse
events. After three months of the study treatment, all patients
met the predeﬁned criteria for good metabolic control. In
contrast, at t15, only 34/40 (85%) were still in good metabolic
control; the remaining six (15%) had HbA1c levels that
exceeded 7.5% (n = 6). On the basis of these ﬁndings, patients
were divided into responders (group R), which included the
34 patients in good glycemic control at t3 and t15, and nonre-
sponders (group NR, 6/40), whose initial response to the
addition of sitagliptin at t3 was not maintained at t15.
3.1. Circulating miRNA Proﬁles of Groups R and NR.We then
compared groups R and NR in terms of miRNA expression
proﬁles in their t0 plasma sample pools. Of the 754 miRNAs
analyzed, 203 (27%) were detected in group NR and 229
(30%) in group R (Supplementary Tables 1 and 2, resp.).
The reliability of our ﬁndings is supported by the fact that
173 miRNAs found in both groups of plasma samples
(Figure 3(a)) included several miRNAs previously known to
be associated with T2D; speciﬁcally, 36% of those were found
in the BioM2MetDisease database (http://www.bio-bigdata.
com/BioM2MetDisease/browse) and identiﬁed in a recent
systematic review by He et al. [24] (Table 2). Similar ﬁndings
emerged when we compared circulating miRNA proﬁles
after 15 months of combined metformin+ sitagliptin ther-
apy. Indeed, the number of detectable miRNAs in the NR
group (213/754, 28%) was comparable to that in the R group
(234/754, 31%) (Supplementary Tables 3 and 4). In addition,
the subset of miRNAs found in both t15 pools (Figure 3(b))
comprised many of those with known links to T2D (39%
in BioM2MetDisease and He et al. [24]) (Table 3). Finally,
151 miRNAs were detected in the plasma pools for both
groups, before (t0) and after the addition of sitagliptin (t15)
(Figure 3(c), Supplementary Table 6). Notably, miRNAs
described to be linked to T2D in previous studies were
detected also in our cohort of elderly T2D patients, further
strengthening their potential role as T2D biomarkers.
Table 3: miRNAs with known links to T2D found in t15 plasma
pools from groups NR and R.
T2D-linked miRNAs at t15
hsa-let-7d
hsa-miR-103
hsa-miR-106b
hsa-miR-122
hsa-miR-126
hsa-miR-130b
hsa-miR-132
hsa-miR-140
hsa-miR-140-3p
hsa-miR-142-3p
hsa-miR-144
hsa-miR-145
hsa-miR-146a
hsa-miR-155
hsa-miR-17-5p
hsa-miR-181a
hsa-miR-186
hsa-miR-18a
hsa-miR-191
hsa-miR-192
hsa-miR-195
hsa-miR-197
hsa-miR-20b
hsa-miR-21
hsa-miR-221
hsa-miR-222
hsa-miR-223
hsa-miR-23a
hsa-miR-24
hsa-miR-26a
hsa-miR-27a
hsa-miR-28-3p
hsa-miR-30d
hsa-miR-30e
hsa-miR-320
hsa-miR-342
hsa-miR-34a
hsa-miR-375
hsa-miR-378
hsa-miR-423-5p
hsa-miR-451a
hsa-miR-483-3p
hsa-miR-486
hsa-miR-571
hsa-miR-572
hsa-miR-593
hsa-miR-661
Table 3: Continued.
T2D-linked miRNAs at t15
hsa-miR-770-5p
hsa-miR-92a
hsa-miR-96
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3.2. Circulating miRNAs in Elderly T2D Patients: Diﬀerential
Expression between Responders and Nonresponders at
Baseline. Our next goal was to identify circulating miRNAs
that might be correlated with a positive metabolic response
to therapy. To this end, we ﬁrst compared the plasma levels
of the 173 miRNAs found in the t0 plasma pools from
groups R and NR. This analysis revealed 20 miRNAs that
were diﬀerentially expressed in the two groups (Table 4,
Figure 4(a)) and might thus be potentially useful for pre-
dicting the response to therapy. As noted in Table 4,
plasma levels of eight of these 20 miRNAs are known to be
potentially inﬂuenced by blood cell contamination [21].
However, this factor is unlikely to have played a role in this
analysis, since occurrence of hemolysis was excluded in all
plasma samples analyzed.
Expression of 10 miRNAs was signiﬁcantly lower in
plasma from NR-t0 versus R-t0 (Table 4, Figure 4(a)); these
included three miRNAs of particular interest: let-7d, miR-
223, and miR-23a, whose expression was reported to be
downregulated in T2D patients when compared to healthy
individuals [6, 12, 25, 26]. Reduced expression of let-7d,
miR-223, and miR-23a in NR patients suggests that these
miRNAs may represent potential biomarkers of response to
sitagliptin therapy.
Other miRNAs resulted to be signiﬁcantly more
expressed in NR-t0 plasma samples. These included miR-
375, whose high expression has been associated with β-cell
dysfunction [27, 28]; miR-571, previously reported to be
hyperexpressed in plasma samples from T2D patients
compared to healthy controls [29]; and miR-378, which was
associated with obesity-related insulin resistance [30, 31].
Increasing evidence has shown the involvement of
miRNAs in the development of the endocrine pancreas,
as well as in the regulation of insulin secretion, insulin signal-
ing, and insulin gene transcription. Indeed, in Dicer-1 condi-
tional knockout mice, loss of miRNAs in β-cells causes major
defects in glucose homeostasis and in insulin secretion, with a
marked reduction in insulin content. Moreover, studies in
rodent models of T2D have revealed changes in miRNA
expression in β-cells [32].
In this context, our data provide evidence that some
miRNAs previously reported as regulators of glucose homeo-
stasis in critical tissues (e.g., endocrine pancreas) may also
represent circulating biomarkers for disease staging and/or
for predicting response to glucose-lowering therapy.
3.3. Circulating miRNAs in the Elderly T2D Patients Who
Responded to Sitagliptin Treatment. To identify miRNAs
potentially modulated by sitagliptin therapy, we compared
miRNA expression levels at t0 and at t15 in plasma samples
from the R group of patients. Twenty-one miRNAs were dif-
ferentially expressed between the two plasma pools (Table 5,
Figure 4(b)). Of note, expression levels of miR-222, previ-
ously reported to be hyperexpressed in plasma samples from
T2D patients versus healthy controls [33], were reduced at
t15 versus t0.
Conversely, three miRNAs were found signiﬁcantly
upregulated in the R-t15 plasma pool (Table 5). These
included miR-126-3p, which was reported to be decreased
in T2D patients (with or without complications) versus
healthy controls [34] and in T2D patients with major cardio-
vascular events [35]. Moreover, this miRNA has been pro-
posed as a biomarker for the detection of prediabetes and
diabetes. miR-30c, another miRNA signiﬁcantly upregulated
in the R-t15 plasma pool, was recently shown to exert protec-
tive eﬀects on diabetic nephropathy [36] and cardiomyopa-
thy [37]. Interestingly, gliptins inhibit the degradation of
several peptides and chemokines and reduce tissue inﬂam-
mation by suppressing macrophage activation and M2 mac-
rophage response. These ﬁndings suggest that glucagon-like
peptide-1- (GLP-1-) based treatments provide additional
beneﬁts beyond glycemic control, including vascular protec-
tion and improved bone health [38].
3.4. Circulating miRNAs in Elderly T2D Patients Who Did
Not Respond to Sitagliptin Treatment. We then compared
miRNA expression levels at t0 and at t15 in plasma samples
from the NR group of patients. As shown in Table 6 and in
Figure 4(c), 21 miRNAs were diﬀerentially expressed
between the two time points, with 5/21 (miR-1208,
miR-550a-3p,miR-30c-5p,miR-1260a, andmiR-1291) show-
ing similar posttreatment changes to groupR (Tables 4 and 5).
Consequently, this observation suggests the exclusion of
these ﬁve miRNAs as possible biomarkers of response to
sitagliptin therapy. Nevertheless, the protective eﬀects of
Table 4: miRNAs that were diﬀerentially expressed in t0 plasma
pools from groups NR and R.
Regulation miRNA
Linear fold
change
P value
Upregulated
in NR-t0
hsa-miR-1208 2.05 1 84E − 02
hsa-miR-1225-3p 2.27 1 20E − 02
hsa-miR-1252-5p 901.88 4 52E − 02
hsa-miR-338-5p 7.56 4 22E − 02
hsa-miR-375 68.83 4 35E − 02
hsa-miR-378∗ 15.26 3 81E − 02
hsa-miR-571 2.39 1 32E − 02
hsa-miR-595 540.84 4 66E − 02
hsa-miR-601∗ 14179.56 4 97E − 02
hsa-miR-885-5p 4.58 3 00E − 02
Downregulated
in NR-t0
hsa-let-7b-5p∗ 0.18 1 53E − 03
hsa-let-7d-5p 0.19 1 11E − 02
hsa-miR-1247-5p 0.20 9 91E − 03
hsa-miR-16-5p∗ 0.21 1 51E − 03
hsa-miR-223-5p 0.32 1 83E − 02
hsa-miR-23a-5p∗ 0.20 8 79E − 03
hsa-miR-30b-5p∗ 0.36 2 74E − 02
hsa-miR-320a 0.23 5 22E − 03
hsa-miR-451a∗ 0.31 3 88E − 03
hsa-miR-93-5p∗ 0.09 2 03E − 02
∗Hemolysis-susceptible miRNAs as reported in Kirschner et al. [21].
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Figure 4: Heat maps showing circulating microRNAs that were diﬀerentially expressed in plasma samples from (a) R and NR patients at
baseline (t0), prior to the addition of sitagliptin to the maximum-dose metformin regimen; (b) R at t0 and after 15 months of sitagliptin
(t15); (c) NR patients at t15 and t0; and (d) R and NR patients at t15.
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miR-30c-5p on diabetic nephropathy and cardiomyopathy
[36, 37] underline the need for further investigation on
the functional role of miR-30c in elderly T2D patients.
A comparison between the diﬀerentially expressed miR-
NAs of NR versus R at baseline (Table 4) and NR at t15 versus
baseline (Table 6) allowed us to observe that one of the miR-
NAs that were more abundant in NR plasma than in R
plasma at baseline, miR-378, increased during the treatment
period, reaching levels in the NR-t15 plasma pool that were
signiﬁcantly higher than those in the NR-t0 pool. This result
allowed us to propose miR-378 as a negative biomarker
candidate for response to sitagliptin therapy.
In this context, our results could open new perspectives
providing the basis for further investigations of the reported
dysregulated miRNAs as markers of response to gliptins.
3.5. Circulating miRNAs in Elderly T2D Patients after 15
Months of Sitagliptin Treatment. To identify miRNAs that
might be aﬀected by sitagliptin treatment, we compared
circulating miRNA levels in plasma samples at t15 from
the two subgroups. Twenty miRNAs were diﬀerentially
expressed in plasma from NR versus R patients (Table 7,
Figure 4(d)). Ten of the 20 miRNAs were signiﬁcantly more
expressed in the plasma samples from the NR group. Among
the upregulated miRNAs, we observed an increased
expression of miR-661 and miR-572 in NR-t15, in accordance
with previous studies performed in T2D patients [26, 39].
miRNAs that were hypoexpressed in the NR-t15 pool
included two of particular interest: miR-126-3p and miR-
223. In the previous analysis of group R, miR-126-3p levels
at t15 were higher than those in the t0 plasma pool, suggesting
that this miRNA is a good candidate biomarker of successful
metabolic response to therapy. Additionally, our previous
comparison of t0 plasma pools from the two groups revealed
substantially lower levels of miR-223 in NR. This miRNA has
already been associated with pancreatic islet β-cell function
and glycemic control, and its expression is reportedly higher
in individuals with pre-T2D and normal controls than in
T2D patients [40, 41]. In light of these results, miR-223
appears to be a possible positive biomarker for monitoring
patients’ responsiveness to sitagliptin therapy.
Finally, we checked for a possible correlation between
diﬀerentially expressed miRNAs, miR-126-3p, miR-223,
and miR-378, and the patients’ clinical features. We did not
observe any statistically signiﬁcant correlation between
miR-126-3p, miR-223, and miR-378 and age, time from
T2D diagnosis, body weight, and HbA1c levels.
An increasing body of evidence has linked diabetes to
cardiovascular disease, renal failure, neuropathy, and osteo-
porosis, especially in elderly individuals, with a consequent
Table 5: miRNAs that were diﬀerentially expressed in t0 and t15
plasma pools from group R.
Regulation miRNA
Linear fold
change
P value
Upregulated
in R-t15
hsa-miR-126-3p 3.30 2 05E − 02
hsa-miR-30c-5p 3.44 4 71E − 03
hsa-miR-331-3p∗ 163.08 3 12E − 02
Downregulated
in R-t15
hsa-miR-1208 0.53 3 55E − 02
hsa-miR-1226-5p 0.42 2 78E − 02
hsa-miR-1260a 0.35 4 07E − 02
hsa-miR-1275 0.24 1 93E − 03
hsa-miR-1291 0.15 3 98E − 02
hsa-miR-1300 0.29 2 08E − 02
hsa-miR-16-5p∗ 0.27 2 23E − 02
hsa-miR-1825 0.50 4 13E − 02
hsa-miR-215-5p 0.05 3 76E − 02
hsa-miR-222-5p 0.26 3 66E − 02
hsa-miR-23a-5p∗ 0.18 4 28E − 03
hsa-miR-25-5p∗ 0.03 3 26E − 02
hsa-miR-451a∗ 0.35 9 49E − 03
hsa-miR-550a-3p 0.34 1 27E − 02
hsa-miR-605-5p 0.19 1 34E − 02
hsa-miR-628-5p 0.00 3 07E − 02
hsa-miR-720 0.41 5 80E − 03
hsa-miR-765 0.01 4 16E − 02
∗Hemolysis-susceptible miRNAs as reported in Kirschner et al. [21].
Table 6: miRNAs that were diﬀerentially expressed in t0 and t15
plasma pools from group NR.
Regulation miRNA
Linear fold
change
P value
Upregulated
in NR-t15
hsa-miR-1247-5p 4.57 2 50E − 02
hsa-miR-126-5p 1.62 4 72E − 02
hsa-miR-151a-3p 2.50 1 87E − 02
hsa-miR-151a-5p 3.73 9 29E − 03
hsa-miR-181a-2-3p 134.20 1 75E − 02
hsa-miR-222-3p 1.85 1 94E − 02
hsa-miR-30a-3p∗ 1.70 4 95E − 02
hsa-miR-30a-5p 1.59 4 80E − 02
hsa-miR-30b-5p 2.18 2 63E − 02
hsa-miR-30c-5p 2.08 3 87E − 02
hsa-miR-320a 2.95 3 40E − 02
hsa-miR-378∗ 2.05 4 62E − 02
hsa-miR-564 3.39 1 41E − 02
hsa-miR-766-3p 3.46 4 62E − 02
hsa-miR-93-5p∗ 6.81 2 63E − 02
Downregulated
in NR-t15
hsa-miR-1208 0.23 3 70E − 03
hsa-miR-1260a 0.37 8 75E − 03
hsa-miR-1291 0.28 1 11E − 02
hsa-miR-345-5p 0.15 9 84E − 03
hsa-miR-550a-3p 0.48 4 08E − 02
hsa-miR-99b-3p∗ 0.29 7 73E − 03
∗Hemolysis-susceptible miRNAs as reported in Kirschner et al. [21].
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increase in mortality, morbidity, and socioeconomic costs.
Reliable biomarkers to predict drug response in these
patients are urgently needed but still lacking. Glucose-
lowering drugs, such as DPP-IVi, are known to diﬀerentially
impact metabolic control and disease-related complications.
Our study is the ﬁrst to provide a description of the circu-
lating miRNAs that can be used as novel biomarkers for
monitoring response to therapy in elderly T2D patients.
4. Conclusion
The results we obtained suggest that miR-378, miR-126-3p,
and miR-223 represent candidate plasma biomarkers for
disease staging and for predicting response to therapy in
T2D elderly patients. High circulating levels of miR-378
appear to be a negative predictor of response to sitagliptin
in elderly T2D patients. Indeed, miR-378 was more
expressed in the NR-t0 plasma pool than in the R-t0 pool.
In addition, its levels in the NR-t15 plasma were even
higher than those found in the NR-t0 pool, and this result
highlights its possible role as a biomarker of resistance to
sitagliptin. In contrast, miR-126-3p and miR-223 seem to
be markers of response to the drug. miR-126-3p levels
have been reported to be lower in T2D patients than in
healthy individuals [34]. Consistently, this miRNA was
not diﬀerentially expressed in the plasma of R and NR
patients at baseline. After 15 months of sitagliptin therapy,
however, plasma levels in responders were signiﬁcantly
higher than those found in the NR group, suggesting that
the addition of the DPP-IVi may have restored miR-126-3p
levels to the range found in healthy subjects. As for
miR-223, its expression at baseline was already signiﬁ-
cantly higher in the R group, and this diﬀerence persisted
after 15 months of sitagliptin addition. This behavior is
consistent with its potential role as a positive predictor
of response to the drug.
Further work is needed to validate the role of these
miRNAs as biomarkers in T2D patients, since this was a
discovery study and the number of NR patients was limited.
Interestingly, circulating miRNAs may reﬂect phenomena
occurring at the level of those organs involved in T2D
pathophysiology (e.g., endocrine pancreas, liver, and adipose
tissue). Therefore, our data provide a snapshot of the circulat-
ing miRNAs that deserve further studies.
The translational relevance of our ﬁndings is immediate;
in fact, data regarding miRNA proﬁles can produce results of
potential impact not only predicting drug response of T2D
elderly patients but also helping in selecting patients that
could be suitable candidates to this therapy.
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